The Cannabis Society Medical Conference - London (Invite Only)
Mackrell, Savoy Hill House, Savoy Hill, London WC2R 0BU
The Cannabis Society is proud to present our
Cannabis Medical Conference on February 17th in London.
Come join us and hear presentations and panels from industry experts discussing the current state of medical cannabis science, cannabis application, laws and market trends within the European Union and abroad
The Cannabis Society (TCS) is an organization focused on progressing the medical cannabis industry in Europe. TCS runs highly-curated, invite-only, professional-only conferences that brings together top cannabis researchers, medical professionals, industry executives, investors and service providers.
TCS is a global organization hosting conferences and events in markets including Europe, North America, South America, Israel and Australia.
Hannah Deacon, Medical Cannabis Clinicians Society
Alfie started having seizures at eight months old which progressively got worse with age. He is diagnosed with PCDH19. The only treatment which worked for Alfie was IV steroids. He was having up to 25 doses a month by the time he was 5 as his condition was getting progressively worse. IV Steriods are extremely dangerous to give on a regular, long term basis. After researching alternative treatments for epilepsy, Hannah, along with her family, took Alfie to Holland in 2017 to be treated by a Paediatric Neurologist with medical cannabis as a last-ditch attempt to save his life.
The medicine worked, but they came home in February 2018, as money had run out but without knowing how to get him his medicine in the UK.
After a long fought four-month battle working alongside End Our Pain and the Government, Alfie’s doctor Professor Mike Barnes, was issued with the first ever personal schedule one license to prescribe medical cannabis in the UK on 19th June 2018. On this day the Home Secretary also announced the review into medical cannabis which helped lead to the law change. On 1st November 2018 the law was changed so full extract cannabis oil can be prescribed on the NHS by specialist clinicians. Alfie now has the first legal NHS prescription in the UK. The campaign which Hannah and End Our Pain ran, played a huge role in ensuring the law was changed and we are very proud of this.
Alfie remains extremely well thanks to securing his prescription and enjoys a full and happy life. Medical Cannabis is not a cure, but it is an amazing treatment for Alfie. My work is now to advocate for those that need medical cannabis on prescription. I support 18 families who are all desperate for help. There are many thousands more, I know what it is like to suffer with a very poorly child and I will do all I can to be the voice for these families and try to ensure they can access medical cannabis on prescription through the NHS.
Chana Greenberger | VP Of Business Development of Brains Bioceutical
Chana Greenberg is VP Business Development at Brains Bioceutical Corp. Brains Bio is one of the only cannabinoid active pharmaceutical ingredient (API) manufacturers in production today with the commercial production capability and the EudraGMDP certification to produce natural CBD API for human and veterinary use. Brains’ BSPG Lab, based in Sandwich, Kent currently manufactures naturally- sourced CBD API with zero THC. Chana has 20 years experience in the startup and innovation space having worked closely with Israeli tech healthcare startups. She is Vice Chair of Hadassah UK which supports Hadassah Medical Organisation in Jerusalem, a pioneering institution in medicinal cannabis since 1964.
Chana holds an MPhil from the University of Cambridge and previously worked in investment banking at Barclays and JP Morgan.
Jonathan Nadler, Managing Director, Lyphe Group
Since founding his first £1m+ revenue business aged 24, Jon has gone on to successfully exit a strategic consultancy, and a CBD oils company. Co-founding a market leading online education platform, The Academy of Medical Cannabis, was the catalyst to securing a Partner role at European Cannabis Fund, ECH. Currently Jon is Group Managing Director at LYPHE GROUP with a portfolio of 6 cannabis companies.
Dr. Dani Gordon
Dr. Dani Gordon is a Canadian and American Board Certified Medical doctor, writer, speaker and published researcher. She completed her family medicine residency at the University of British Columbia and went on to become an American board qualified specialist in Integrative Medicine, the newest American physician sub-specialty of conventional medicine.
In her Canadian medical practice she was one of the early adopters of cannabis medicine, treating thousands of patients with medical cannabis in an integrative chronic disease referral practice.
She now lives in London and trained the first UK physicians in cannabis medicine, consults for governments, companies and international organizations on cannabis and is a founding member and current Vice Chair of the UK Medical Cannabis Clinicians Society (MCCS).
Prof. Mike Barnes, Neurologist, University of Newcastle
Professor Mike Barnes is a neurologist based at the University of Newcastle. He has a long standing interest in cannabis as a medicine and assisted with the development of the first cannabis medicine - Sativex. In 2016 he wrote, with his daughter, a definitive report for the APPG on Drug Policy Reform on the efficacy of cannabis. He then helped the family of Alfie Dingley to obtain the first license in the UK for cannabis for Alfie's resistant epilepsy. He then campaigned, with others, for the law change which was successful and on 1st November 2018 allowed specialist doctors to prescribe cannabis. Since then very few prescriptions have been written and his focus now is on education of doctors so that more prescriptions will be written. He now is Chief Medical Officer of the Lyphe Group and runs a cannabis consultancy with Hannah Deacon.
Alexej Pikovsky, Founder & CEO, Alphagreen Group
Alexej Pikovsky is the CEO and Co-Founder of Alphagreen Group, a European distribution platform for high-quality wellness and medical cannabis products. Prior to Alphagreen, Alexej has been working as an investor for a large-cap private equity fund and a family office where he ran the venture capital operations. He gained operational and board-level experience working closely with Compo Expert, the largest European specialty fertiliser business, as well as leading their trade sale. Alexej started his career in M&A at Nomura where he advised on several multi-billion deals in Natural Resources and Chemicals. Alexej holds a Masters from Imperial College London and is a Fellow of the German National Academic Foundation.
Alex Brooks, Senior Analyst Canaccord Genuity
Alex Brooks is a senior analyst at Canaccord Genuity, covering UK-listed materials technology, energy services, and medical cannabis companies. He has covered a wide range of industrial & energy companies over twenty years in the City, working on projects from large-scale emerging market IPOs to small secondary fundraises. He started his career at JPMorgan Asset Management, and has also worked sell-side at UBS & Credit Suisse.
Andrew Rosen, Head of Global Business Development, Cannatrek
Andrew Rosen is the Head of Global Business Development for Cannatrek, a medical cannabis company in Australia focused on superior cultivation and medical product development. He has assisted numerous companies in the cannabis industry to expand and strategize activities in international markets. He also holds a position as the Director of Strategic Partnerships for Cannamerx, the leading commodities exchange in the Cannabis and Hemp industry with over 250 members globally.
Jens Kramer, VP Europe operations, Avicanna Inc.
An essential leader in driving business growth, efficiency and transformational initiatives, Jens has provided strategic counsel and operational guidance to several startup companies in Berlin. Previously, he has been responsible for design and implementation of scale-up plans for companies entering new markets and has successfully launched services in several countries. Capable of quickly assessing and identifying levers for driving potential distribution opportunities in Europe, Jens brings with him valuable entrepreneurial experience and region-specific expertise to Avicanna’s team with direct accountability for consistently delivering business objectives through multiple market sectors across Europe. He has attained his Bachelor of International Management from ISM University and has pursued his International Masters in Management from EADA Business School in Barcelona.
Dr. Leon Barron
Dr Barron is a General Practitioner based in London. A strong interest in mental health, chronic disease and chronic pain management has led to an interest in medical cannabis as an alternative therapy for patients who have not found conventional therapies to be effective. He enjoys the challenge of managing the physical, psychological and social components of health with a focus on the patient as a whole rather than just symptoms and disease in question. He has undertaken specialist training in medical cannabis prescribing from leading physicians from Canada and Israel, who are considered global experts in this emerging field of medicine.
Dr Barron is a contributor and lecturer for The Academy of Medical Cannabis, Resident GP at The Medical Cannabis Clinics and Executive Committee Member of The Medical Cannabis Clinicians Society. He also continues to undertake regular NHS work and is a visiting tutor for undergraduate medicine at University College London.
Bek Muslimov, Leafy Tunnel
Bek is a Partner and member of the founding team at Leafy Tunnel, an investment firm dedicated to investing in early stage companies focused on mental health and palliative care. His recent investments at Leafy Tunnel includes Wundr Co. (European cannabis company), ATAI Life Sciences (biotech platform curing mental health disorders) and Synthesis Institute (medically supervised retreats).
Prior to Leafy Tunnel Bek has been an Investment Director at Blue Wire Capital and has been investing in European technology and life science companies for the past 7 years. While at Blue Wire he has led investments in technology companies Monzo, Superawesome, Homehero, Ocean Harvest, Ihateironing. Bek is an MBA graduate of London Business School.
David Badcock, CEO, Drug Science
David Badcock has held strategic positions in the substance misuse treatment sector for over 15 years. During this time, he has met and worked with thousands of individuals who have turned their lives around to lead healthy, successful lives free from the burden of drug addiction. He was previously the Chief Executive Officer of Mainliners, a national treatment organization focusing on harm reduction and blood borne viruses, and also a senior manager at national drug treatment provider Addaction. In addition, David was a committee member for the Cambridge Ethnic Community Forum from 2002-2005, the chair of the Alliance (supporting people who receive prescribed medication for drug dependency) from 2007-2010, and scientific committee member for the influential London Joint Working Group for Substance Misuse and Hepatitis C from 2010-2015. David specializes in creating unique partnerships with organizations and companies who share a joint vision to help the most marginalized and vulnerable members of our communities.
Peter Pottier, Materia Ventures
Sean McLintock, The Cannabis Fund
If you are an established national or international company, and are looking to learn more about the cannabis space, please reach out to email@example.com for more information.
***More information about the Cannabis Society here.
This listing has no upcoming events
Service Providers (Lawyers, Accountants, Recruiters and Consultants)